Log in

ASX:VBSVectus Biosystems Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. Vectus Biosystems Limited was founded in 2005 and is based in Rosebery, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 2 9662 4144



Sales & Book Value

Annual Sales$346.00
Book ValueA($0.16) per share



Next Earnings DateN/A
OptionableNot Optionable

Receive VBS News and Ratings via Email

Sign-up to receive the latest news and ratings for VBS and its competitors with MarketBeat's FREE daily newsletter.

Vectus Biosystems (ASX:VBS) Frequently Asked Questions

Has Vectus Biosystems been receiving favorable news coverage?

Press coverage about VBS stock has been trending somewhat negative on Sunday, according to InfoTrie. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vectus Biosystems earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutVectus Biosystems.

Who are some of Vectus Biosystems' key competitors?

Who are Vectus Biosystems' key executives?

Vectus Biosystems' management team includes the following people:
  • Dr. Karen Annette Duggan, CEO & Exec. Director
  • Prof. Graham Jon MacDonald AM, M.D., BSc (Med), BS, FRACP, FRCP, FANZCC, Consultant
  • Mr. Robert John Waring BEc, CA, FCIS, FFin, FAICD, Company Sec.

What is Vectus Biosystems' stock symbol?

Vectus Biosystems trades on the ASX under the ticker symbol "VBS."

How big of a company is Vectus Biosystems?

Vectus Biosystems has a market capitalization of $0.00 and generates $346.00 in revenue each year.

What is Vectus Biosystems' official website?

The official website for Vectus Biosystems is www.vectusbiosystems.com.au.

How can I contact Vectus Biosystems?

The company can be reached via phone at 61 2 9662 4144.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.